AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative Quality of Recovery Scale
Description: To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:30PM ± 1.5 hrs (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.
Study NCT02230605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative Quality of Recovery Scale
Description: To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:30PM ± 1.5 hrs (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.
Study NCT03192163 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: 31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.
Study NCT04400890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol vs placebo given for 15 days.
Study NCT04400890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 100,000 IU given on day one.
Study NCT04400890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 100,000 IU given on day one.
Study NCT01956591 — intervention group
Intervention type: DRUG
Intervention: Oxybutynin
Description: All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
Study NCT02102191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-cigarette
Description: smoking cigarette without tobacco
Study NCT01191684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02102191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cigarette
Description: smoking cigarette with tobacco
Study NCT03374176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500 mg / Metronidazole 250 mg
Description: Subjects were instructed to take a capsule three times a day for 7 days
Study NCT03374176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg
Description: Subjects were instructed to take a capsule three times a day for 7 days
Study NCT03725969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Camel milk
Description: Camel Milk administered 10 minutes before a mixed meal of carbohydrate and protein; 2-week washout between interventions
Study NCT03725969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cow milk
Description: Cow milk administered 10 minutes before a mixed meal of carbohydrate and protein;2-week washout between interventions
Study NCT02087553 — intervention group
Intervention type: BIOLOGICAL
Intervention: Transfusion of red blood cells
Description: (non-experimental) PRBC transfusion
Study NCT01191684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT01191684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT03147027 — intervention group
Intervention type: OTHER
Intervention: medication
Description: medication to prevent sustained VT and ICD therapies
Study NCT00262704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simulated case-based customized learning
Description: Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback
Study NCT00262704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simulated case based customized learning + leader feedback
Description: Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
Study NCT00543647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg tablet
Study NCT00543647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01539629 — intervention group
Intervention type: DEVICE
Intervention: Cardiac pacing
Description: Cadiac pacing via a pulse generator and implaned intracardiac leads.
Study NCT01449825 — intervention group
Intervention type: DRUG
Intervention: Pazopanib use
Description: Treatment with pazopanib
Study NCT01449825 — intervention group
Intervention type: DRUG
Intervention: Use of sunitinib, bevacizumab, or sorafenib
Description: Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
Study NCT02843386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy by Fotemustin
Description: Fotemustin is given for 6 cycles :~* One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.~* Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21.
Study NCT02843386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intensive surveillance
Description: Intensive surveillance~* Total duration: 3 years.~* liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months.
Study NCT01127360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravitreal injections
Study NCT01318616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training of the hip adductors
Description: Adductor strength training
Study NCT03511339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TecTraum device
Description: A non-invasive hypothermic therapy (cold therapy) TecTraum device that provides localized cooling of the head and neck.
Study NCT02580058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: 10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles
Study NCT02580058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLD
Description: PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
Study NCT02580058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
Study NCT02201810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate reduction intervention
Study NCT02201810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recycling Group
Study NCT02201810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Group
Study NCT02201810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive QL
Study NCT03578406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPV E6-specific TCR-T cells
Description: Patients were infused with HPV E6-specific TCR-T cells
Study NCT05400460 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anatomical single-bundle reconstruction（ASBR method）
Description: 406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the ASBR group to receive anatomic single-bundle reconstruction.We used hamstring as an autograft in the operation, and we chose the anatomical footprint of the anterior cruciate ligament for the positioning of the bone tunnel.Arthroscopic ASB ACL reconstruction was conducted with AMP technique.
Study NCT05400460 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Double-bundle reconstruction （DBR method）
Description: 406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the DBR group to receive double bundle reconstruction.The hamstring autograft is still used for double-bundle reconstruction. The surgical approach is to treat the native ligaments as anteromedial bundles and posterolateral bundles and restore the structure of the two bundles of ligaments in the process of a
Study NCT05400460 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Central axial single-bundle reconstruction（CASBR group）
Description: 406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to CASBR group.Arthroscopic ASB ACL reconstruction was conducted with transtibial technique and using Hamstring as autograft.Single-bundle reconstruction is used in CASBR reconstruction surgery.~The footprint of the implant on the lateral femoral condyle was chosen to be the location of the AMB bone canal in DB reconstruction surgery while the footprint of the implant on the tibial plateau was chosen to be the location of the bone canal of the PLB in DB reconstruction surgery.
Study NCT05400460 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: rehabilitation training protocol
Description: The rehabilitation program for all patients followed a standardized Process. The first day after surgery, quadriceps sets, straight-leg raises, and prone hangs were initiated. All of the patients were allowed to walk with crutches and braces but with no weightbearing. The range of motion (ROM) progressed from 0 to 90 degrees 3 to 7 days postoperatively and reached 115 degrees within fourth week. Closed kinetic chain exercises and full weightbearing were started in the sixth week. Patients progressed to running without braces at 4 to 6 months.
Study NCT05400460 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educate patients on return to sports and the importance of quadriceps strength
Description: Patients were interviewed by telephone preoperatively, 6 months postoperatively, and 1 year postoperatively to ask about Tegner scores and to encourage reasonable return to sports from 6 months postoperatively.~Inform patients of the possibility of osteoarthritis in patients undergoing ACL reconstruction preoperatively, 6 months postoperatively, and 1 year postoperatively in telephone interviews.Tell the patient that return to sports and quadriceps strength is a must if the knee cartilage damage is to improve.
Study NCT01127360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravitreal injections
Study NCT01127360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injections
Study NCT01127360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injections
Study NCT04126668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 with fed or fasting
Description: The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
Study NCT02350205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Self assembled skin substitute (SASS)
Description: All patients in Phase B will receive Self assembled skin substitute (SASS)
Study NCT03615534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Lifestyle Changes
Description: Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.
Study NCT03615534 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic Lifestyle Changes
Description: Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.
Study NCT03615534 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03615534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Study NCT03615534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wax Matrix Extended Release Niacin (WMER Niacin)
Study NCT01191684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT01191684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified vaccinia virus ankara vaccine expressing p53
Description: Given SC
Study NCT04162275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finamine tablets
Description: taken Finamine tablets orally
Study NCT04162275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finamine tablets
Description: taken Finamine tablets orally
Study NCT04162275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: taken Placebo tablets orally
Study NCT03745469 — intervention group
Intervention type: DEVICE
Intervention: Smartphone
Description: A standard smartphone will be used for browsing the internet for two different durations (10 and 30 minutes)
Study NCT00327132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole, Amoxicillin, Clarithromycin
Study NCT00932802 — intervention group
Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
Study NCT01339182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-Somatropin
Description: Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-Somatropin, 10mcg/kg.
Study NCT01339182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Somatropin
Description: Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 30mcg/kg.
Study NCT01339182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Somatropin
Description: Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 60mcg/kg.
Study NCT01339182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Somatropin
Description: Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 120mcg/kg.
Study NCT01339182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Somatropin
Description: Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 200mcg/kg.
Study NCT03267589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562
Description: Three different combination are being tested. Each cohort has different combination
Study NCT02537470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biphasic Remogliflozin Etabonate
Description: Experimental Drug
Study NCT02537470 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo Comparator
Study NCT01011283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Description: decitabine 20 mg/m\^2 /day intravenous (IV) infusion for 5 days every 28 days
Study NCT01011283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azacitidine
Description: azacitidine 75 mg/m\^2 /day subcutaneous (SC) injection for 7 days every 28 days
Study NCT03528577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zero-dose
Description: Treatment A
Study NCT03528577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zero-dose
Description: Treatment A
Study NCT03528577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zero-dose
Description: Treatment A
Study NCT03528577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 90 mcg of PROAIR® HFA
Description: Treatment B
Study NCT03528577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 90 mcg of PROAIR® HFA
Description: Treatment B
Study NCT03528577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mcg of PROAIR® HFA
Description: Treatment B
Study NCT03528577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 180 mcg of 90 mcg of PROAIR® HFA
Description: Treatment C
Study NCT03528577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 180 mcg of 90 mcg of PROAIR® HFA
Description: Treatment C
Study NCT03528577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 180 mcg of 90 mcg of PROAIR® HFA
Description: Treatment C
Study NCT03528577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 90 mcg of albuterol sulfate inhalation aerosol
Description: Treatment D
Study NCT03528577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 90 mcg of albuterol sulfate inhalation aerosol
Description: Treatment D
Study NCT03528577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mcg of albuterol sulfate inhalation aerosol
Description: Treatment D
Study NCT02216162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm A: adapted physical activity + enhanced geriatric follow-up
Description: Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.~A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36).
Study NCT02216162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Usual clinical follow-up
Study NCT05406999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
Study NCT05406999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
Study NCT05406999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg (250 mg×4 tablets) once daily, orally
Study NCT05406999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone tablets
Description: 5 mg once daily, orally.
Study NCT05406999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg (40 mg× 4 tablets) once daily, orally.
Study NCT05406999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240 mg (60 mg×4 tablets) once daily, orally.
Study NCT05406999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darotamide
Description: 600 mg (300 mg × 2 tablets) twice daily, orally.
Study NCT05406999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezvilutamide
Description: 240 mg (80 mg × 3 tablets) once daily orally
Study NCT05406999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor
Description: The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
Study NCT05406999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted radical prostatectomy
Description: Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
Study NCT05406999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy
Description: Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
Study NCT01755637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole tablets 400 mg
Study NCT01755637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole tablets 400 mg
Study NCT00762684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559
Description: TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
Study NCT00762684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.